TUXARIN ER Drug Patent Profile
✉ Email this page to a colleague
When do Tuxarin Er patents expire, and what generic alternatives are available?
Tuxarin Er is a drug marketed by Mainpointe and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in TUXARIN ER is chlorpheniramine maleate; codeine phosphate. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the chlorpheniramine maleate; codeine phosphate profile page.
DrugPatentWatch® Generic Entry Outlook for Tuxarin Er
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 3, 2032. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TUXARIN ER?
- What are the global sales for TUXARIN ER?
- What is Average Wholesale Price for TUXARIN ER?
Summary for TUXARIN ER
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| DailyMed Link: | TUXARIN ER at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TUXARIN ER
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for TUXARIN ER
| Drug Class | Histamine-1 Receptor Antagonist Opioid Agonist |
| Mechanism of Action | Full Opioid Agonists Histamine H1 Receptor Antagonists |
US Patents and Regulatory Information for TUXARIN ER
TUXARIN ER is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TUXARIN ER is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TUXARIN ER
Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mainpointe | TUXARIN ER | chlorpheniramine maleate; codeine phosphate | TABLET, EXTENDED RELEASE;ORAL | 206323-001 | Jun 22, 2015 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Mainpointe | TUXARIN ER | chlorpheniramine maleate; codeine phosphate | TABLET, EXTENDED RELEASE;ORAL | 206323-001 | Jun 22, 2015 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TUXARIN ER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mainpointe | TUXARIN ER | chlorpheniramine maleate; codeine phosphate | TABLET, EXTENDED RELEASE;ORAL | 206323-001 | Jun 22, 2015 | ⤷ Sign Up | ⤷ Sign Up |
| Mainpointe | TUXARIN ER | chlorpheniramine maleate; codeine phosphate | TABLET, EXTENDED RELEASE;ORAL | 206323-001 | Jun 22, 2015 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TUXARIN ER
See the table below for patents covering TUXARIN ER around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
